Ontology highlight
ABSTRACT:
SUBMITTER: Zhao Y
PROVIDER: S-EPMC10983105 | biostudies-literature | 2024 Mar
REPOSITORIES: biostudies-literature
Zhao Yuanyuan Y Chen Gang G Li Xingya X Wu Jingxun J Chang Baoping B Hu Sheng S Yang Shujun S Xu Ting T Liu Yilan Y Wang Ni N Zhang Li L Huang Yan Y
Cell reports. Medicine 20240301 3
KN046, a bispecific antibody targeting PD-L1 and CTLA-4, presents a promising therapeutic option for metastatic non-small cell lung cancer (NSCLC). In this multicenter phase 2 trial, patients with nonsquamous (non-sq) NSCLC receive pemetrexed, whereas those with sq-NSCLC receive paclitaxel, plus KN046 and carboplatin. Following four cycles, maintenance therapy includes KN046 with pemetrexed for non-sq-NSCLC and KN046 for sq-NSCLC. The objective response rate is 46.0%, and the median duration of ...[more]